A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the Db-Ig platform, which...

Full description

Bibliographic Details
Main Authors: Alexander Rau, Katharina Kocher, Mirjam Rommel, Lennart Kühl, Maximilian Albrecht, Hannes Gotthard, Nadine Aschmoneit, Bettina Noll, Monilola A. Olayioye, Roland E. Kontermann, Oliver Seifert
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
Bispecific antibody
diabody-ig
Db-Ig
dual targeting
HER2
HER3
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2021.1902034

Similar Items

Similar Items